# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, ", PMV Pharma", )))) today announced a partnershi...
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target...
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by...
Jefferies analyst Kambiz Yazdi initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target o...
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated pat...
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.